Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

Since its introduction in 1988, recombinant human erythropoietin (epoetin) has been standard treatment for patients with anemia due to chronic kidney disease. From 1998 to 2004, nearly 200 epoetin-treated persons with chronic kidney disease developed antibodies to epoetin, resulting in pure red cell...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Bennett, Charles L., Cournoyer, Denis, Carson, Kenneth R., Rossert, Jerome, Luminari, Stefano, Evens, Andrew M., Locatelli, Francesco, Belknap, Steven M., McKoy, June M., Lyons, E. Alison, Kim, Benjamin, Sharma, Rishi, Costello, Stacey, Toffelmire, Edwin B., Wells, George A., Messner, Hans A., Yarnold, Paul R., Trifilio, Steven M., Raisch, Dennis W., Kuzel, Timothy M., Nissenson, Allen, Lim, Lay-Cheng, Tallman, Martin S., Casadevall, Nicole
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: The American Society of Hematology 2005
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895064/
https://ncbi.nlm.nih.gov/pubmed/16099877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-02-0508
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak